BlackRock Inc. acquired a new position in shares of Urogen Pharma Ltd (NASDAQ:URGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 89,790 shares of the company’s stock, valued at approximately $4,468,000. BlackRock Inc. owned 0.65% of Urogen Pharma as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently bought and sold shares of the company. Swiss National Bank bought a new position in shares of Urogen Pharma during the 2nd quarter worth about $856,000. Clal Insurance Enterprises Holdings Ltd increased its stake in Urogen Pharma by 9.3% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 310,000 shares of the company’s stock valued at $15,426,000 after acquiring an additional 26,500 shares during the period. Alps Advisors Inc. increased its stake in Urogen Pharma by 10.0% in the second quarter. Alps Advisors Inc. now owns 22,451 shares of the company’s stock valued at $1,117,000 after acquiring an additional 2,045 shares during the period. Menora Mivtachim Holdings LTD. increased its stake in Urogen Pharma by 22.2% in the second quarter. Menora Mivtachim Holdings LTD. now owns 2,499,870 shares of the company’s stock valued at $124,394,000 after acquiring an additional 454,241 shares during the period. Finally, Bainco International Investors increased its stake in Urogen Pharma by 67.2% in the second quarter. Bainco International Investors now owns 175,461 shares of the company’s stock valued at $8,731,000 after acquiring an additional 70,500 shares during the period. Institutional investors own 69.93% of the company’s stock.
NASDAQ URGN opened at $46.67 on Friday. The stock has a market capitalization of $602.04 million, a P/E ratio of -21.81 and a beta of 2.39. Urogen Pharma Ltd has a twelve month low of $36.66 and a twelve month high of $69.57.
Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, August 14th. The company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.25). The business had revenue of $0.36 million during the quarter. Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%. On average, equities analysts expect that Urogen Pharma Ltd will post -4.12 EPS for the current year.
A number of research firms recently weighed in on URGN. Cowen reissued a “buy” rating on shares of Urogen Pharma in a research note on Tuesday, August 14th. Stifel Nicolaus began coverage on shares of Urogen Pharma in a research note on Thursday, September 13th. They issued a “buy” rating and a $70.00 target price on the stock. Oppenheimer set a $75.00 target price on shares of Urogen Pharma and gave the company a “buy” rating in a research note on Tuesday, August 14th. Zacks Investment Research cut shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Finally, Jefferies Financial Group began coverage on shares of Urogen Pharma in a research note on Thursday. They issued a “buy” rating and a $77.00 target price on the stock. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $67.60.
TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/blackrock-inc-acquires-shares-of-89790-urogen-pharma-ltd-urgn.html.
Urogen Pharma Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.